Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are rare diseases encompassing pancreatic (PanNETs) and ileal NETs (SINETs), characterized by heterogeneous somatostatin receptors (SSTRs) expression. Treatments for inoperable GEP-NETs are limited, and SSTR-targeted Peptide Receptor Radionuclide Therapy (PRRT) achieves variable responses. Prognostic biomarkers for the management of GEP-NET patients are required. 18F-FDG uptake is a prognostic indicator of aggressiveness in GEP-NETs. This study aims to identify circulating and measurable prognostic miRNAs associated with 18FFDG- PET/CT status, higher risk and lower response to PRRT.
Circulating hsa-miR-5096 predicts 18F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors / Bocchini, Martine; Tazzari, Marcella; Ravaioli, Sara; Piccinini, Filippo; Foca, Flavia; Tebaldi, Michela; Nicolini, Fabio; Grassi, Ilaria; Severi, Stefano; Calogero, Raffaele Adolfo; Arigoni, Maddalena; Schrader, Joerg; Mazza, Massimiliano; Paganelli, Giovanni. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - ELETTRONICO. - 13:(2023), pp. 1136331.1-1136331.18. [10.3389/fonc.2023.1136331]
Circulating hsa-miR-5096 predicts 18F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors
Bocchini, Martine;Piccinini, Filippo;Grassi, Ilaria;Paganelli, Giovanni
2023
Abstract
Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are rare diseases encompassing pancreatic (PanNETs) and ileal NETs (SINETs), characterized by heterogeneous somatostatin receptors (SSTRs) expression. Treatments for inoperable GEP-NETs are limited, and SSTR-targeted Peptide Receptor Radionuclide Therapy (PRRT) achieves variable responses. Prognostic biomarkers for the management of GEP-NET patients are required. 18F-FDG uptake is a prognostic indicator of aggressiveness in GEP-NETs. This study aims to identify circulating and measurable prognostic miRNAs associated with 18FFDG- PET/CT status, higher risk and lower response to PRRT.| File | Dimensione | Formato | |
|---|---|---|---|
|
0073_2023_FrontiersInOnc_Bocchini.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
5.6 MB
Formato
Adobe PDF
|
5.6 MB | Adobe PDF | Visualizza/Apri |
|
1136331.zip
accesso aperto
Tipo:
File Supplementare
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
2.43 MB
Formato
Zip File
|
2.43 MB | Zip File | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
